MX2021015457A - Formulaciones de dihidromiricetina y un permeabilizante. - Google Patents

Formulaciones de dihidromiricetina y un permeabilizante.

Info

Publication number
MX2021015457A
MX2021015457A MX2021015457A MX2021015457A MX2021015457A MX 2021015457 A MX2021015457 A MX 2021015457A MX 2021015457 A MX2021015457 A MX 2021015457A MX 2021015457 A MX2021015457 A MX 2021015457A MX 2021015457 A MX2021015457 A MX 2021015457A
Authority
MX
Mexico
Prior art keywords
dihydromyricetin
formulations
permeabilizer
fatty acid
dhm
Prior art date
Application number
MX2021015457A
Other languages
English (en)
Inventor
Brooks Powell
Robert K Prud''homme
Nicholas Caggiano
Chang Tian
Original Assignee
Univ Princeton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Princeton filed Critical Univ Princeton
Publication of MX2021015457A publication Critical patent/MX2021015457A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Formulaciones que incluyen dihidromiricetina (DHM) y una sal de ácido graso o un ácido graso.
MX2021015457A 2019-06-14 2020-06-12 Formulaciones de dihidromiricetina y un permeabilizante. MX2021015457A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962861895P 2019-06-14 2019-06-14
PCT/US2020/037542 WO2020252346A1 (en) 2019-06-14 2020-06-12 Formulations of dihydromyricetin and a permeabilizer

Publications (1)

Publication Number Publication Date
MX2021015457A true MX2021015457A (es) 2022-04-06

Family

ID=73781573

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015457A MX2021015457A (es) 2019-06-14 2020-06-12 Formulaciones de dihidromiricetina y un permeabilizante.

Country Status (5)

Country Link
US (1) US20220265600A1 (es)
EP (1) EP3982953A4 (es)
CA (1) CA3143203C (es)
MX (1) MX2021015457A (es)
WO (1) WO2020252346A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019055539A1 (en) * 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
GB202109464D0 (en) 2021-06-30 2021-08-11 Norwegian Univ Sci & Tech Ntnu Soft gel capsule
US20230052453A1 (en) * 2021-08-05 2023-02-16 Moxy Distribution, Inc. Compositions and methods for relieving effects of alcohol consumption
CN116036034B (zh) * 2023-03-31 2023-06-02 北京佳福瑞生物科技有限公司 一种用于神经精神类疾病治疗的复合药剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165976A (en) * 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
EP1390383B1 (en) * 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Antisense permeation enhancers
EP1401503B1 (en) * 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
CN100389766C (zh) * 2003-10-30 2008-05-28 湖南省中医药研究院 二氢杨梅素在制备药物中的应用
US8623329B1 (en) * 2009-10-13 2014-01-07 Aerophase, Inc. Method for the treatment of lung tumors
WO2014066632A1 (en) * 2012-10-24 2014-05-01 Cargill, Incorporated Phospholipid-containing emulsifier composition
BR112015002626A2 (pt) * 2012-11-29 2017-09-26 Yeda Res & Dev métodos para prevenção de metástases tumorais, tratamento e prognostico do câncer e identificação dos agentes que são inibidores da metástase putativa
US9603830B2 (en) * 2014-05-29 2017-03-28 Thriveplus Llc Compositions and methods for preventing and recovery from detrimental effects of alcohol consumption
CN105213250A (zh) * 2015-09-08 2016-01-06 上海应用技术学院 一种复配型天然抗菌剂及其制备方法和在化妆品中的应用
ES2845688T3 (es) * 2016-01-28 2021-07-27 Capsugel Belgium Nv Composiciones y cápsulas duras resultantes que comprenden concentrados alimentarios colorantes hidrófilos
US20190105293A1 (en) * 2016-03-24 2019-04-11 Phoenix Pharmaceuticals Australia Pty Ltd Formulation and method for the prevention and/or treatment of hangover symptoms
US10357529B2 (en) * 2016-11-07 2019-07-23 Rvrs, Llc Natural formulation for treating hangover
WO2019050969A1 (en) * 2017-09-06 2019-03-14 Prud'homme, Robert, K. FORMULATIONS OF DIHYDROMYRICETIN NANOPARTICLES
US20200147032A1 (en) * 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them
WO2020099937A2 (en) * 2018-11-14 2020-05-22 Prud'homme, Robert, K. Dihydromyricetin spray-dried dispersion formulations and methods for forming them

Also Published As

Publication number Publication date
EP3982953A1 (en) 2022-04-20
WO2020252346A1 (en) 2020-12-17
CA3143203A1 (en) 2020-12-17
EP3982953A4 (en) 2023-07-19
US20220265600A1 (en) 2022-08-25
CA3143203C (en) 2024-05-28

Similar Documents

Publication Publication Date Title
MX2021015457A (es) Formulaciones de dihidromiricetina y un permeabilizante.
WO2021127404A8 (en) Tricyclic pyridones and pyrimidones
CR20200393A (es) Picolinamidas como fungicidas
MX2022001421A (es) Compuesto tetracíclico, método de preparación y uso del mismo.
MX2020006115A (es) Inhibidores de la vía de respuesta al estrés integrada.
PH12020500655A1 (en) Compounds
MY197631A (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
EA026931B9 (ru) Гербицидно и фунгицидно действующие 5-оксизамещенные 3-фенилизоксазолин-5-карбоксамиды и 5-оксизамещенные 3-фенилизоксазолин-5-тиоамиды или их соли
MX2021003559A (es) Inhibidores de vap-1.
MX2021015210A (es) Inhibidores de la via de respuesta al estres integrada.
PH12020552146A1 (en) Micellar delivery method
MX2017006083A (es) Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma.
MX2020013269A (es) Inhibidores de la vía de respuesta al estrés integrada.
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
PH12018502620A1 (en) Protoporphyrinogen oxidase variants and methods and compositions for conferring and/or enhancing herbicide tolerance using the same
MX2020002043A (es) Mezclas de inhibidores de la protoporfirinogeno oxidasa.
MX2021001727A (es) Preparacion de esteres de acido (met)acrilico.
EP4234561A3 (en) Antiviral prodrugs and nanoformulations thereof
MX2022007275A (es) Composiciones de acidos biliares y compuestos de fenilbutirato.
EP4009770A4 (en) ELECTROMAGNETIC TREATMENT OF CROPS
MX2022006653A (es) Compuestos para modular la actividad de fxr y usos de los mismos.
MX2021016050A (es) Formulaciones transdermicas.
MX2021003731A (es) Inhibidores de vap-1.
MX2022001723A (es) Formulaciones de cannabidiol (cbd) y usos de las mismas.
MX2019011613A (es) Formulaciones de acido 1-amino-1-ciclopropanocarboxilico.